Sara J Esposite

US Patent:

20130079326, Mar 28, 2013

Filed:

May 24, 2011

Appl. No.:

13/699547

Inventors:

Hon-Chung Tsui - Shanghai, CN
Sunil Paliwal - Monroe Township NJ, US
Hyunjin M. Kim - Linvingston NJ, US
Angela D. Kerekes - Plainfield NJ, US
Mary Ann Caplen - Sayreville NJ, US
Sara J. Esposite - Neptune NJ, US
Brian A. McKittrick - New Vernon NJ, US
Thierry Olivier Fischmann - Scotch Plains NJ, US
Ronald J. Doll - Convent Station NJ, US
Matthew Paul Rainka - Schenectady NY, US

International Classification:

A61K 45/06
A61K 31/454
C07D 401/14
A61K 31/4545
C07D 405/14
A61K 31/4178
A61K 31/4995
A61K 31/437
C07D 413/14
A61K 31/5377
A61K 31/551
C07D 403/04
C07D 409/14
A61K 31/506

US Classification:

51421018, 546211, 514326, 546194, 514318, 546210, 544333, 514256, 544349, 514249, 546113, 514300, 546 16, 514278, 544130, 5142358, 540556, 514221, 5483124, 514392

Abstract:

The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R, R, R, and Rare as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.

US Patent:

20170369507, Dec 28, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532549

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew L. Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Michael J. Ellis - Boston MA, US
Sara Esposite - Neptune NJ, US
Qingmei Hong - Kenilworth NJ, US
Chunhui Huang - Kenilworth NJ, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NC, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Ryan D. Otte - Boston MA, US
Michael H. Reutershan - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Feroze Ujjainwalla - Kenilworth NJ, US
Catherine White - Boston MA, US
Zhicai Wu - Kenilworth NJ, US
Yang Yu - Kenilworth NJ, US
Kake Zhao - Kenilworth NJ, US
Craig R. Gibeau - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 498/08
C07D 471/04
C07D 498/10
C07D 471/08
A01N 43/00

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

US Patent:

20170362220, Dec 21, 2017

Filed:

Dec 1, 2015

Appl. No.:

15/532552

Inventors:

- Rahway NJ, US
Stephane L. Bogen - Rahway NJ, US
Matthew L. Childers - Boston MA, US
Francesc Xavier Fradera Llinas - Boston MA, US
Michael J. Ellis - Boston MA, US
Sara Esposite - Neptune NJ, US
Dawn M. Hoffman - Boston MA, US
Chunhui Huang - Kenilworth NJ, US
Solomon D. Kattar - Boston MA, US
Alexander J. Kim - Rahway NJ, US
John W. Lampe - Cary NJ, US
Michelle R. Machacek - Boston MA, US
Daniel R. McMasters - Boston MA, US
Michael H. Reutershan - Boston MA, US
Nunzio Sciammetta - Boston MA, US
Patrick Pengcheng Shao - Kenilworth NJ, US
David L. Sloman - Boston MA, US
Wanying Sun - Kenilworth NJ, US
Feroze Ujjainwalla - Kenilworth NJ, US
Zhicai Wu - Kenilworth NJ, US
Yang Yu - Kenilworth NJ, US
Craig R. Gibeau - Boston MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 519/00
C07D 471/14

Abstract:

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes (I); wherein A is —C(R)═ or —N═; and X is selected from the group consisting of: (II-i), and (II-ii). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

US Patent:

20140128339, May 8, 2014

Filed:

Oct 15, 2013

Appl. No.:

14/054424

Inventors:

Vinay Girijavallabhan - Whippany NJ, US
Stephane Bogen - Somerset NJ, US
Quang T. Truong - Morganville NJ, US
Ping Chen - Edison NJ, US
Angela Kerekes - Plainfield NJ, US
Frank Bennett - Cranford NJ, US
Sara Esposite - Neptune NJ, US
Qingmei Hong - Scotch Plains NJ, US
Ian Davies - Princeton NJ, US

International Classification:

C07H 19/06
A61K 45/06
A61K 31/7072
C07H 19/10
A61K 31/7068

US Classification:

514 51, 536 2851, 536 285, 536 2853, 536 268, 536 2626, 514 49, 514 50

Abstract:

The present invention relates to 2′-Methyl Substituted Nucleoside Derivatives of Formula (I):and pharmaceutically acceptable salts thereof, wherein R, R, Rand R, are as defined herein. The present invention also relates to compositions comprising at least one 2′-Methyl Substituted Nucleoside Derivative, and methods of using the 2′-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.